- Home
- REBN vs ADXN Comparison
REBN vs ADXN Comparison
Compare REBN & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | ADXN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 10.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | REBN | ADXN |
|---|---|---|
| Price | $1.48 | $7.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.1K | 6.7K |
| Earning Date | 11-19-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,663,303.00 | $198,824.00 |
| Revenue This Year | $335.98 | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.09 | N/A |
| 52 Week Low | $1.20 | $6.51 |
| 52 Week High | $8.30 | $12.05 |
Technical Indicators
Market Signals| Indicator | REBN | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 46.21 |
| Support Level | $1.38 | $7.66 |
| Resistance Level | $1.55 | $8.90 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 29.94 | 38.62 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.